| Cash Flow | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Amortization of debt issuance costs and discounts | 0 | 53,722 |
| Change in fair value of derivative liabilities | 0 | 6,312 |
| Gain on extinguishment of debt | 0 | 326,345 |
| Accrued expenses | NaN | -453,445 |
| Accrued interest - related party | 0 | NaN |
| Accrued interest | 0 | 14,190 |
| Shares issued in exchange for services | NaN | 250,000 |
| Net loss | -1,146,096 | -5,167,569 |
| Stock-based compensation | 345,396 | 496,864 |
| Prepaid expenses and other current assets | NaN | 148,531 |
| Prepaid expenses | -88,282 | NaN |
| Accounts payable - trade | -140,781 | 496,910 |
| Accrued expenses | 256,901 | NaN |
| Net cash used in operating activities | -596,298 | -4,777,892 |
| Repayment of notes payable- related party | 0 | 275,000 |
| Proceeds from issuance of common stock and warrants in private placement | 0 | 7,161,504 |
| Repayment of financing liability | 92,407 | NaN |
| Proceeds from issuance of common stock in private placement | 652,000 | NaN |
| Payment of issuance costs related to private placement | 121,160 | 1,683,523 |
| Net cash provided by financing activities | 438,433 | 5,202,981 |
| Net (decrease) increase in cash and cash equivalents | -157,865 | 425,089 |
| Cash and cash equivalents - beginning of period | 459,174 | 34,085 |
| Cash and cash equivalents - end of period | 301,309 | 459,174 |
ADAPTIN BIO, INC. (APTN)
ADAPTIN BIO, INC. (APTN)